Is your heart aging faster than you are?

November 26, 2007

MONTREAL, Quebec (November 26, 2007) - Despite the increasing evidence that managing high cholesterol reduces cardiovascular events, many people do not achieve recommended lipid levels. This is due, in part, to patients' lack of understanding about their risk factors and the potential benefits of lifestyle modifications and therapy.

A new study undertaken by the McGill University Health Centre (MUHC), the Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP), now provides definitive evidence that communicating the future risk of cardiovascular events to high-risk patients improves the treatment of cardiovascular risk factors, such as high cholesterol. CHECK-UP is the first successful study of its kind worldwide and is published in this week's Archives of Internal Medicine.

"The economic burden of cardiovascular disease is substantial to the Canadian healthcare system, but even more important are the devastating human costs associated with the disease," says Dr. Steven Grover, lead author and Director of the McGill Cardiovascular Health Improvement Program (CHIP). "The CHECK-UP study shows that when Canadians become more actively involved in the decisions surrounding their care, they are better equipped to manage their risk for future cardiovascular events."

Patients who entered the CHECK-UP study had high cholesterol requiring treatment as per the Canadian Working Group Lipid Guidelines. Included were those who had diabetes, established cardiovascular disease or multiple risk factors for cardiovascular disease. The results of the study show that lipid therapy is enhanced when patients are informed about their cardiovascular risk and when they receive ongoing feedback from their doctor about the impact lifestyle modifications and statin therapy has on their cardiovascular risk. These patients saw a bigger drop in their lipid levels; in fact, the higher a patient's cardiovascular risk, the greater their risk profile was impacted.

The computerized risk profiles used in the CHECK-UP study were based on data from the Framingham Heart Study, and the Cardiovascular Life Expectancy model previously published by the McGill research team. Each patient's future risk of cardiovascular disease was based on their age, gender, blood pressure, blood lipids, and whether or not they smoked, had diabetes or a previous cardiac event such as a heart attack. For example, a 43-year-old male smoker who is substantially overweight, with above-average cholesterol and blood pressure levels, in actual fact has a cardiovascular age equivalent to that of a 51-year-old. If all these risk factors were managed according to current Canadian guidelines, he could reduce his cardiovascular age to that of a 42-year-old.

"We are very excited about the results of the CHECK-UP study," says Dr. Grover. "CHECK-UP is the first study of its kind in Canada to focus on the importance of communicating calculated cardiovascular risk to patients who are at high-risk for a cardiovascular event, such as a heart attack or stroke. Discussing a patient's coronary risk and taking the necessary steps to manage it is an important step in improving preventive care."

Cardiovascular disease, including heart disease and stroke, is the leading cause of death in Canada. Research shows that approximately 80 per cent of Canadians have at least one modifiable risk factor for cardiovascular disease, such as high cholesterol, hypertension, obesity and a sedentary lifestyle.
-end-
ABOUT THE CHECK-UP STUDY

The CHECK-UP study enrolled 230 primary care physicians and 2,687 patients who were at increased risk of a heart attack due to high blood lipid levels. Among these subjects, 1,510 received a full report of their coronary risk at each doctor's appointment over the course of a year. This report contained their cardiovascular age* and their risk of developing a cardiovascular event within eight years. These calculations are based on key elements related directly to lifestyle, such as tobacco use, cholesterol level and blood pressure, and allow doctors to demonstrate and quantify the precise impact of lifestyle and medical treatment on a patient's health. In the study, patients were randomized to receive usual care or ongoing feedback at routine appointments regarding their calculated cardiovascular risk and the change in this risk following lifestyle and/or statin therapy to treat high cholesterol. At follow-up appointments, any subsequent improvements in a patient's risk factors due to medication or lifestyle changes were used to recalculate the patient's cardiovascular age. This gave both the patient and his or her physician clear feedback on how the treatment had impacted the patient's state of health. The CHECK-UP study was supported by an unrestricted educational grant from Pfizer Canada and designed in partnership with McGill University Health Centre (MUHC).

MCGILL UNIVERSITY HEALTH CENTRE (MUHC)

The MUHC is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. The MUHC is a merger of five teaching hospitals affiliated with the Faculty of Medicine at McGill University, the Montreal Children's, Montreal General, Royal Victoria, and Montreal Neurological Hospitals, as well as the Montreal Chest Institute. Building on the tradition of medical leadership of the founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field, and to contribute to the development of new knowledge.

PFIZER CANADA INC

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world's leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer's ongoing research and development activities focus on a wide range of therapeutic areas following our guiding aspiration: working for a healthier world. For more information, visit www.pfizer.ca.

Note to editors:

* Cardiovascular age is calculated as the patient's age minus the difference between their estimated remaining life expectancy and the average remaining life expectancy of life expectancy of Canadians the same age and sex.

FOR MORE INFORMATION, PLEASE CONTACT:

Isabelle Kling
McGill University Health Centre
(514) 934-1934, ext. 36419
isabelle.kling@muhc.mcgill.ca

Laura Espinoza/Carolyn Santillan
Edelman (Toronto)
(416) 979-1120, ext. 245/395
laura.espinoza@edelman.com
carolyn.santillan@edelman.com

Alexandra Menear
Edelman (Montreal)
(514) 844-6665, ext. 226
alexandra.menear@edelman.com

McGill University Health Centre

Related Blood Pressure Articles from Brightsurf:

Children who take steroids at increased risk for diabetes, high blood pressure, blood clots
Children who take oral steroids to treat asthma or autoimmune diseases have an increased risk of diabetes, high blood pressure, and blood clots, according to Rutgers researchers.

High blood pressure treatment linked to less risk for drop in blood pressure upon standing
Treatment to lower blood pressure did not increase and may decrease the risk of extreme drops in blood pressure upon standing from a sitting position.

Changes in blood pressure control over 2 decades among US adults with high blood pressure
National survey data were used to examine how blood pressure control changed overall among U.S. adults with high blood pressure between 1999-2000 and 2017-2018 and by age, race, insurance type and access to health care.

Transient increase in blood pressure promotes some blood vessel growth
Blood vessels are the body's transportation system, carrying oxygen and nutrients to cells and whisking away waste.

Effect of reducing blood pressure medications on blood pressure control in older adults
Whether the amount of blood pressure medications taken by older adults could be reduced safely and without a significant change in short-term blood pressure control was the objective of this randomized clinical trial that included 534 adults 80 and older.

Brain blood flow sensor discovery could aid treatments for high blood pressure & dementia
A study led by researchers at UCL has discovered the mechanism that allows the brain to monitor its own blood supply, a finding in rats which may help to find new treatments for human conditions including hypertension (high blood pressure) and dementia.

Here's something that will raise your blood pressure
The apelin receptor (APJ) has been presumed to play an important role in the contraction of blood vessels involved in blood pressure regulation.

New strategy for treating high blood pressure
The key to treating blood pressure might lie in people who are 'resistant' to developing high blood pressure even when they eat high salt diets, shows new research published today in Experimental Physiology.

Arm cuff blood pressure measurements may fall short for predicting heart disease risk in some people with resistant high blood pressure
A measurement of central blood pressure in people with difficult-to-treat high blood pressure could help reduce risk of heart disease better than traditional arm cuff readings for some patients, according to preliminary research presented at the American Heart Association's Hypertension 2019 Scientific Sessions.

Heating pads may lower blood pressure in people with high blood pressure when lying down
In people with supine hypertension due to autonomic failure, a condition that increases blood pressure when lying down, overnight heat therapy significantly decreased systolic blood pressure compared to a placebo.

Read More: Blood Pressure News and Blood Pressure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.